new
coronaviru
outbreak
ongo
pandem
caus
sever
acut
respiratori
syndrom
coronaviru
new
coronaviru
belong
subfamili
share
genet
sequenc
sarscov
caus
agent
epidem
start
end
consid
clinic
impact
new
outbreak
highli
import
studi
potenti
respons
human
immun
system
infect
well
role
virusspecif
cell
blymphocyt
moreov
specif
data
product
igg
igm
crucial
allow
rapid
identif
infect
paper
also
describ
import
sensit
specif
rapid
test
inde
test
repres
import
immunolog
tool
aim
identifi
precis
phase
infect
order
undertak
appropri
pharmacolog
treatment
lastli
provid
overview
pharmacolog
treatment
aim
reduc
inflammatori
process
underli
infect
need
discoveri
new
vaccin
viru
belong
famili
coronavirus
positivestrand
rna
virus
character
spheric
shape
provid
typic
crown
appear
virus
first
identifi
classifi
four
distinct
subfamili
alpha
betacoronavirus
mainli
infect
mammal
gamma
deltacoronavirus
inclin
infect
bird
induc
mild
infect
upper
lower
respiratori
tract
other
caus
seriou
symptom
lead
respiratori
failur
date
seven
type
coronaviru
abl
infect
human
identifi
common
virus
caus
common
cold
also
sever
lower
respiratori
tract
infect
apart
three
beta
coronavirus
call
sarscov
infect
occur
fever
fatigu
dri
cough
sever
case
pneumonia
acut
respiratori
syndrom
kidney
failur
case
infect
fatal
consid
immunopatholog
aspect
patient
infect
experi
mild
null
symptom
howev
sever
case
patient
may
experi
lymphopenia
interstiti
pneumonia
high
level
proinflammatori
cytokin
includ
gcsf
result
massiv
releas
cytokin
gener
socal
cytokin
storm
turn
induc
acut
respiratori
distress
syndrom
ard
respiratori
failur
organ
failur
potenti
patient
death
mechan
basi
rational
administr
tocilizumab
monoclon
antibodi
inhibit
ligand
bind
human
receptor
recent
approv
china
reduc
lung
complic
patient
infect
apart
tocilizumab
counteract
inflammatori
phenomena
deriv
mainli
activ
drug
mainli
repres
antivir
combin
treatment
lopinavirritonavir
remdesivir
favipiravir
umifenovir
current
evalu
treatment
instanc
recent
data
share
italian
ministri
health
reveal
among
medic
combin
treatment
lopinavirritonavir
current
decreas
total
number
lymphocyt
viral
infect
adapt
immun
respons
virusspecif
cell
cellmedi
immun
blymphocyt
humor
immun
play
key
role
inde
activ
helper
lymphocyt
contribut
exacerb
inflammatori
respons
b
lymphocyt
provid
product
specif
antibodi
aim
neutral
viru
wide
recogn
prior
product
high
affin
immunoglobulin
g
igg
longterm
immun
immunolog
memori
immunoglobulin
igm
provid
first
line
defens
viral
infect
accordingli
detect
igm
serum
reveal
recent
exposur
viru
detect
igg
suggest
exposur
occur
sever
day
howev
specif
data
respons
human
immun
system
infect
still
lack
base
knowledg
acquir
past
year
sarscov
merscov
infect
report
sarscov
infect
igm
could
detect
patient
blood
day
igg
could
detect
day
similarli
merscov
infect
seroconvers
observ
second
third
week
diseas
onset
type
coronaviru
infect
delay
weak
antibodi
respons
associ
sever
outcom
thevarajan
et
al
defin
potenti
mechan
implement
immun
system
cours
infect
studi
carri
use
blood
sampl
patient
return
wuhan
symptom
includ
lethargi
sore
throat
dri
cough
fever
blood
sampl
taken
differ
stage
diseas
recoveri
result
reveal
igm
igg
progress
increas
day
day
specif
research
show
day
onset
similarli
zhou
pet
al
found
patient
develop
virusspecif
igm
peak
day
diseas
onset
transit
igg
occur
within
second
week
order
appli
rapid
test
abl
detect
presenc
specif
igm
igg
import
consid
igm
valu
tend
disappear
within
week
sinc
begin
infect
therefor
consid
symptom
infect
occur
within
day
case
difficult
accur
determin
patient
contract
viru
consequ
immunoglobulin
valu
high
enough
time
test
fals
neg
could
record
infect
also
transmit
among
asymptomat
patient
high
viral
load
without
show
symptom
quit
difficult
manag
spread
viru
order
solv
problem
use
rapid
test
combin
detect
igg
igm
would
desir
rapid
test
abl
simultan
detect
presenc
igm
igg
serum
within
minut
predict
stage
patient
infect
sensit
specif
test
evalu
blood
sampl
patient
test
posit
nasopharyng
swab
infect
patient
test
neg
asymptomat
potenti
risk
develop
infect
base
epidemiolog
criteria
result
studi
show
blood
sampl
patient
infect
test
posit
hand
blood
sampl
nasopharyng
swab
neg
test
posit
well
therefor
test
show
sensit
first
second
group
patient
respect
furthermor
posit
patient
igm
igg
antibodi
simultan
therefor
rapid
test
combin
detect
igg
igm
specif
prove
sensit
specif
howev
certain
risk
regist
fals
posit
fals
neg
case
moment
test
repres
import
immunolog
test
aim
identifi
precis
phase
infect
order
undertak
appropri
pharmacolog
treatment
therefor
desir
rapid
test
becom
sensit
specif
order
quickli
identifi
patient
prevent
rapid
transmiss
viru
lastli
develop
vaccin
urgent
need
accord
shang
w
et
al
combin
subunit
vaccin
adjuv
may
repres
good
strategi
speed
clinic
develop
author
also
report
research
would
bring
new
vaccin
approxim
week
wait
specif
vaccin
similar
approach
use
immunotherapi
treatment
cancer
seriou
viral
respiratori
infect
could
repres
option
prevent
treatment
instanc
solut
could
repres
passiv
immun
administr
serum
contain
specif
antibodi
taken
patient
unlik
activ
immun
approach
requir
activ
recipi
immun
respons
gener
immedi
immun
respons
howev
would
emerg
solut
substitut
vaccin
therapi
conflict
declar
